Lentiviral vector-mediated knockdown of *Lrb* in the arcuate nucleus promotes diet-induced obesity in rats

J Bian, X M Bai, Y L Zhao, L Zhang and Z J Liu

Department of Pediatrics, The Second Affiliated Hospital, Dalian Medical University, 467 Zhongshan Road, Shahekou District, Dalian 116027, China

Correspondence
should be addressed
to Z J Liu
Email
liuzj_1963@yahoo.com.cn

Abstract

Obesity is currently a worldwide pandemic. Leptin resistance is a main mechanism of obese human and rodents. The downregulation of the long form of the leptin receptor (*Lrb*) was involved in leptin resistance in diet-induced obese rats. In the studies, we investigated whether arcuate nucleus (ARC) silencing of *Lrb* would promote diet-induced obesity in rats. Lentiviral vectors expressing *Lrb*-shRNA were administered to 5-week-old male rats by ARC injection. Following viral delivery, the rats were provided with a high-fat diet (HFD) or a chow diet (CD). After 8 weeks of the diet, serum leptin, and insulin concentrations were measured by RIA, gene expression of *Lrb* in the ARC was detected by a real-time RT-PCR, and leptin signaling was examined by western blot. The *Lrb*-shRNA knocked down the expression of *Lrb* mRNA in infected regions by 54% for the HFD rats and 47% for the CD rats respectively. The *Lrb* knockdown reduced Stats3 activation and increased expression of *Npy* mRNA. The rats with reduced *Lrb* in the ARC showed a significant increase in energy intake and body weight (BW) again when fed with a HFD. By contrast, there were no effects of *Lrb* reduction on energy intake or BW when rats maintained on a low-fat chow. Our results provide evidence that *Lrb* knockdown selectively in the ARC promotes diet-induced obesity and associated metabolic complications in rats.

Key Words

- obesity
- metabolism
- leptin
- receptors

*Journal of Molecular
Endocrinology*
(2013) 51, 27–35

Introduction

Obesity has become one of the most important health problems in the world. Except for some rare types of monogenic defects (Farooqi & O'Rahilly 2006), obesity occurs due to the complex combination of multiple environmental and genetic factors (Galgani & Ravussin 2008). The hyperleptinemia in obese patients and rodents supports that leptin resistance or insensitivity to the action of leptin is a common mechanism of obesity (Fleisch *et al.* 2007, Augustine & Grattan 2008).

The responsiveness to leptin may vary according to the metabolic conditions (Widdowson *et al.* 1997) and leptin resistance is relevant to leptin receptors (*Lrb*) or their downstream signaling pathway (Martin *et al.* 2000). Our previous studies showed that the leptin concentrations were high in obese children (Nakanishi *et al.* 2001) and that gene expression of *Lrb* was reduced in diet-induced obese rats (Liu *et al.* 2007), which implied that downregulation of *Lrb* was involved in leptin resistance.

The suppressor of cytokine signaling 3 (SOCS3) is a negative-feedback regulator of leptin and insulin signaling. In diet-induced obese rodents, the expression of *Socs3* is significantly stimulated in the hypothalamus, providing a negative control for leptin and insulin signaling (Dunn *et al.* 2005, Picardi *et al.* 2008). It is well known that genetic mutations in the *Lrb* (Zucker fatty rats) lead to obesity and diabetes. However, it is not known whether incomplete knockdown of *Lrb* in arcuate nucleus (ARC) in normally developed wild-type animals is sufficient to alter body weight (BW) on a regular chow or a high-fat diet (HFD). RNA interference (RNAi) has been proven to be ideal for long-term, stable knockdown of gene expression (Makinen *et al.* 2006, Kourtidis *et al.* 2007), which is critical for understanding and studying how reducing expression of disease-relevant genes cause disease phenotypes over extended period. In the studies, we used RNAi to investigate the possible interaction between gene and diet in the development of obesity phenotypes.

Materials and methods

Design and construction of shRNA

Lentivirus vector construction and packaging were performed by Shanghai Kangchen Biological Engineering & Technology Co. Ltd. (Shanghai, China). According to *Lrb* mRNA sequence (AF287268), the target oligonucleotides were designed at the position in gene sequence from 854 gene site, two cDNA template chains were designed and BamHI, XhoI enzyme cleavage sites were introduced at the terminals (Fig. 1A). The sequences of shRNA directed against the rat *Lrb* were as follows (the sense and antisense sequences are underlined, italics indicates loop): sense, 5'-GATCCC TCTCTCGGATACATCTCTTTGATATCCGAGAGATGTATCCGAGACGATTTTTTCCAAC-3', antisense, 5'-TCGAGTTGGAAAAATCGTCTCGGATACATCTCTCGGATATCAAAGAGATGTATCCGAGACGA GG-3', and the sequences of scrambled shRNA were sense, 5'-GATCCCGTCTCCGAACGTGTACAGTTCAAGAGACGTGACAGTTTCGGAGAATTTTTTCCAAA-3', and antisense, 5'-TCGATTTGGAAAAATTTCTCCGAACGTGTACAGTTCTCTTGAAAACGTGACAGTTTCGGAGAACG-3'. The double-stranded oligonucleotides were cloned into the linear vector containing enhanced green fluorescent protein (EGFP) gene. *Escherichia coli* were transformed with the recombinant linear vector and selected to obtain positive clones by PCR. The *Lrb*-shRNA recombinant plasmid and the scrambled shRNA control plasmid were isolated from the positive clones using plasmid preparation kit. The cloned

sequence was confirmed by electrophoresis and sequencing. The *Lrb*-shRNA recombinant plasmids were transfected into the rat C6 glioma cells (American Type Culture Collection, Manassas, VA, USA) to determine the inhibiting efficiency by immunofluorescence microscopy and a real-time RT-PCR. The RNAi protocol specifically reduced the expression of *Lrb* mRNA by ~80% in transfected rat glioma cells (Liu *et al.* 2009).

Animal and RNAi protocols

Five-week-old male Sprague Dawley rats ($n=20$ /group) weighing 100–120 g were housed in pairs at a constant room temperature of 20–22 °C with a 12 h light:12 h darkness schedule. The procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals.

Stereotaxic surgery was performed under anesthesia by i.p. injection of sodium pentobarbital (60 mg/kg BW). For ARC viral delivery, Hamilton syringe needles were placed on a stereotaxic frame into the following coordinates from bregma: anterior–posterior 2.8 mm, lateral 0.4 mm, and vertical –9.5 mm. One microliter of purified virus (2.0×10^9 infectious particles/ml) was delivered per side over a 5-min period. The injector was kept in the place for an additional 5 min before it was withdrawn in order to diffuse and to prevent backflow through the needle track. After the microinjection, the rats were fed one of two diets: the chow diet (CD; 2.6 kcal/g with 6% kcal from fat) or HFD (4.7 kcal/g with 45% kcal from fat) (Trophic Animal Feed High-Tech Co. Ltd., Nantong China) for 8 weeks. The food intake was measured daily. The BW was recorded daily for 4 weeks, after which it was measured weekly.

After 8 weeks of the diet, glucose tolerance tests were performed. The animals were fasted overnight and glucose was administered intraperitoneally (1 g/kg BW) between 0900 and 1000 h, and blood samples were taken by tail vein droplets at 0, 15, 30, 60, 90, and 120 min. Plasma glucose was measured using the glucose oxidase method (Invitrogen). Two days later, the animals were fasted overnight again and were anesthetized by i.p. injection of pentobarbital between 0900 and 1100 h. Thirty minutes later, blood was taken by heart puncture, and serum was immediately separated through centrifugation and kept under –20 °C.

Isolation of hypothalamic tissues

The brains were harvested and the hypothalami were immediately dissected with the landmarks. The hypothalami were bordered anteriorly by the rostral border of the optic chiasma, posteriorly by the region just rostral to the

Figure 1

Lentivirus vector-mediated knockdown of *Lrb* in the hypothalamus. Schematic of shRNA expression vector (A). The vectors contain a BamHI site, a 19-nucleotide sense sequence, a loop sequence, a 19-nucleotide antisense sequence, a RNA polymerase III site, and an XhoI site. Fluorescent microscopic image showing EGFP expression (B). The lentiviral vectors expressing *Lrb*-shRNA or scrambled shRNA were stereotactically injected into the arcuate nucleus (ARC). The rats were killed at 8 weeks after viral delivery. Fluorescent microscopic image showing EGFP expression in the

ARC but not in the ventromedial hypothalamic nucleus (VMN). Scale bar, 100 μ m. Immunohistochemistry showing *Lrb* protein expression in ARC (C) and VMN (E). Scale bar, 100 μ m. Quantitative analysis of *Lrb* mRNA expression by a real-time RT-PCR in ARC (D) and VMN (F). The level of *Lrb* mRNA was normalized to the GAPDH values. The white bar represents scrambled control group, and the black bar represents *Lrb*-shRNA group. $n=8-10$ per group. The results are shown as mean $\pm$ s.e.m. * $P<0.01$ vs controls. Con, control.

mammillary bodies, and laterally 1 mm medial to the hypothalamic sulci. The depth of the excised tissue was ~ 2 mm. The tissue samples were frozen in liquid nitrogen and stored at -80°C until further use. For immunohistochemistry, the rats were perfused with cold PBS followed by 4% paraformaldehyde. The brains were removed, post-fixed in paraformaldehyde, and embedded with paraffin wax.

The GFP was used as a visual marker of effective transduction of the lentivirus vector and detection of the injection site, which was confirmed by visualizing GFP fluorescence using a fluorescent microscopy (Fig. 1B). The rats that did not express GFP in the ARC were excluded from any further analysis. Except for brain death after injection, anesthesia and other causes of death, and incorrect injection location, the final success rate of the animal model was 54%.

Leptin signaling studies

To examine the role of *Lrb* knockdown on leptin signaling, the rats treated with *Lrb*-shRNA or scrambled shRNA (described earlier) were placed on a CD or a HFD for 8 weeks. The rats ($n=5-6$ for each group) were fasted overnight and then injected intraperitoneally with 15 mg/kg leptin or saline. One hour later, the rats were killed and the hypothalami were dissected. Two tissue pieces (one from each hemisphere) from individual animal were separately frozen at -80°C until further use. One piece was isolated to assess *Socs3* mRNA expression via real-time PCR and the other was for quantification of phosphorylated Stat3 (pStat3) levels by western blot analysis.

Biochemical and hormonal assays

The blood samples were collected by terminal cardiac puncture and centrifuged at 1006.2 g for 10 min. The concentrations of serum leptin and insulin were determined with RIA kits provided by Linco Research (St Charles, MO, USA), and the concentrations of serum glucose, cholesterol, and triglyceride were determined with an automatic measuring analyzer (Olympus AU 1000, Tokyo, Japan).

Immunohistochemistry

Paraffin-embedded tissues including ARC were cut to a thickness of $5\text{ }\mu\text{m}$ on a microtome. The sections were deparaffinized in xylene and rehydrated using a graded series of ethanol. A method of streptavidin-biotin-HRP was used after heat-induced epitope retrieval. Briefly, endogenous peroxidase activity was blocked for 15 min in 3% hydrogen peroxide and then the slides were incubated in blocking solution for 15 min at room temperature. Thereafter, the slides were incubated with the first primary antibody for *Lrb* (Abcam Ltd., Hongkong, China) at a dilution of 1:100 overnight at 4°C . Detection of the immunoreaction was achieved using the secondary biotinylated antibody and the streptavidin/HRP complex (incubating for 20 min respectively). Diaminobenzidine/ H_2O_2 was used as the chromogen and hematoxylin as the counterstain.

RNA isolation and real-time RT-PCR

In order to determine the inhibiting efficiencies of RNAi, the expression levels of *Lrb* mRNA in ARC were measured by a real-time RT-PCR technique. To further confirm the specificity of *Lrb*-shRNA in ARC, the adjacent brain

sections were used to evaluate the expression levels of *Lrb* mRNA in ventromedial hypothalamic nucleus (VMN). The frozen samples were cut serially on a cryostat at -12°C into $300\text{ }\mu\text{m}$ sections centered on both the paraventricular nucleus of the hypothalamus and the central portion of the ARC at the level of the compact zone of the dorsomedial hypothalamic nucleus. These latter sections also contained the midpoint of the VMN and the lateral hypothalamus. The sections were placed in RNA Later (Ambion) until micropunched. The micropunches of the ARC and VMN were performed by the method of Palkovits (1973). The tissue slices were placed on the base of a stereotaxic frame and visualized under an operating microscope. The syringe to which the punches were attached was mounted on the stereotaxic arm, and the punches were made under microscopic guidance.

Total RNA was extracted from ARC tissue using the TRIzol method and purified with RNaseH according to the manufacturer's instruction (Invitrogen). The punched samples were kept in RNA for <2 weeks before being reversed transcribed to cDNA. A real-time RT-PCR technique was used to determine relative expression levels of *Lrb*, *Socs3*, and *Npy* mRNA. PCR was performed using the following primers, *Lrb* forward: 5'-TGTTCTGGGCA-CAAGGACTTA-3', reverse: 5'-ACCATAGCTGCTGGTACC-ATCTCA-3'; *Socs3* forward: 5'-CTGGACCCATTCGGGA-GTTC-3', reverse: 5'-AACTGGGAGCTACCGACCATTG-3'; and NPY forward: 5'-ACCAGGCAGAGATATGGCAAGA-3', reverse: 5'-GGACATTTTCTGTGCTTTCTCTCATT-3'. The reactions were performed using a Light Cycler Real-Time PCR analysis (Roche Diagnostics Co.), and all amplifications were carried out in a total reaction volume of $20\text{ }\mu\text{l}$ containing 40 pmol forward and reverse primers and $2\text{ }\mu\text{l}$ cDNA by a Two-Step RT-PCR kit (TaKaRa Biotechnology Co. Dalian, China). *Lrb* and *Socs3* were amplified using 40 cycles and NPY using 35 cycles. GAPDH (forward: 5'-GGCACAGTCAAGGCTGAGAATG-3' and reverse: 5'-ATGGTGGTGAAGACGCCAGTA-3') was used for internal normalization. The expression levels were calculated by the standard curve method.

Protein extracts and western blot analysis

The samples from ARC (described earlier) were homogenized in ice-cold lysis buffer containing 20 mmol/l MOPS, 2 mmol/l EGTA, 5 mmol/l EDTA, 40 mmol/l β -glycerophosphate, 30 mmol/l sodium fluoride, 10 mmol/l sodium pyrophosphate, 2 mmol/l orthovanadate, 0.5% NP-40, and complete protease inhibitors cocktail (Roche). The protein concentrations were

Figure 2

Effect of *Lrb* knockdown in the ARC on energy intake in rats. The changes in caloric consumption of the HFD rats with scrambled shRNA (the white squares), the HFD rats with *Lrb*-shRNA (the black squares), the CD rats with scrambled shRNA (the white circles), and the CD rats with *Lrb*-shRNA (the black circles). $n=10-12$ per group. The results are shown as mean $\pm$ S.E.M. * $P<0.01$ vs controls.

measured with the BCA protein quantification kit (Pierce, Rockford, IL, USA). Equal amounts (50 μ g) of protein were loaded and fractionated in each lane of 10% polyacrylamide-SDS gels. After the protein was transferred to PVDF membranes, the membranes were blocked with 5% defatted milk for 60 min at room temperature and incubated with the phosphotyrosine-specific antibody against Stat3 Tyr705 (Santa Cruz Biotechnologies) at a dilution of 1:500 for overnight at 4 °C. Then the membranes were probed with the HRP-conjugated secondary antibody at a dilution of 1:5000. Blots were detected using the ECL detection kit (Amersham Life Sciences). The same blots were stripped and reblotted with an antibody specific to Stat3 to normalize the pStat3 levels. For quantitative analysis, the density of blots for pStat3 and total Stat3 was measured and expressed as ratios of pStat3 to total Stat3.

Statistical analysis

Statistical analysis was performed using the SPSS Software (version 11; SPSS, Inc., Chicago IL, USA). Two-way ANOVA was used to analyze energy intake and BW data (time and diet were used as the variables). One-way ANOVA with independent samples *t*-test was performed to analyze RT-PCR, western blot, and biochemical data. Differences were considered significant if $P<0.05$. Data are expressed as the means $\pm$ S.E.M.

Results

Lrb knockdown in the ARC

The rats were killed at 8 weeks after viral delivery to the ARC. Immunostaining showed that *Lrb*-shRNA inhibited *Lrb* protein expression in the ARC in both the CD group and the HFD group (Fig. 1C), but there was no effect in the VMN (Fig. 1E). The expression of *Lrb* mRNA was measured by real-time fluorescence PCR. The RNAi protocol specifically reduced the expression of *Lrb* mRNA by 47% for the CD group and 54% for the HFD group respectively (Fig. 1D). Similarly, there was no effect on *Lrb* mRNA expression in the VMN in both the CD group and the HFD group (Fig. 1F).

Reduction of *Lrb* in the ARC promotes diet-induced obesity and associated metabolic complications

After viral delivery, the rats were placed on a HFD or a CD for 8 weeks. Food intake was minimal immediately following surgery; however, all groups recovered to normal 2–3 days later. The *Lrb*-shRNA-treated rats displayed a significant increase in caloric consumption when maintained on the HFD, an effect that became apparent after 16 days of viral delivery and remained throughout the study. There were no effects of *Lrb* reduction on energy intake on the CD (Fig. 2).

Figure 3

Effect of *Lrb* knockdown in the ARC on body weight in rats. The lentiviral vector was stereotactically delivered into the ARC. After the microinjection, rats were fed a high-fat diet (HFD) or a regular chow diet (CD) for 8 weeks. The white squares represent scrambled control rats on the HFD, the black squares represent *Lrb*-treated rats on the HFD, the white circles represent scrambled rats on the CD, and the black circles represent *Lrb*-treated rats on the CD. $n=10-12$ per group. The results are shown as mean $\pm$ S.E.M. * $P<0.05$ vs controls and ** $P<0.01$ vs controls.

Figure 4

Glucose tolerance tests in rats. At the end of the study, glucose tolerance tests were performed. Glucose tolerance tests (A). The white squares represent scrambled shRNA rats on the HFD, the black squares represent *Lrb*-shRNA rats on the HFD, the white circles represent scrambled shRNA rats on the CD, and the black circles represent *Lrb*-shRNA rats on the CD. Area under the glucose tolerance curves (B). The white bars represent scrambled shRNA rats, and the black bars represent *Lrb*-shRNA rats. $n = 10-12$ per group. The results are shown as mean $\pm$ S.E.M. * $P < 0.05$ vs controls.

Lrb reduction in the ARC resulted in increased BW gain in HFD rats, an effect that appeared from the third week after viral delivery and persisted throughout the study. In contrast, there were no differences in BW in rats with targeted ARC *Lrb*-shRNA injections on the CD (Fig. 3).

Table 1 Biochemical parameters in rats after 8-week diet. Biochemical parameters represent the average $\pm$ S.E.M. $n = 8-10$ per group

	CD		HFD	
	Scrambled shRNA	<i>Lrb</i> -shRNA	Scrambled shRNA	<i>Lrb</i> -shRNA
Glucose (mmol/l)	4.49 $\pm$ 0.76	5.12 $\pm$ 0.63	6.30 $\pm$ 1.18	7.60 $\pm$ 1.39*
Triglyceride (mmol/l)	0.43 $\pm$ 0.12	0.45 $\pm$ 0.13	0.57 $\pm$ 0.13	0.68 $\pm$ 0.14
Cholesterol (mmol/l)	0.88 $\pm$ 0.20	0.90 $\pm$ 0.19	1.10 $\pm$ 0.16	1.31 $\pm$ 0.14 [†]
Leptin (ng/ml)	8.04 $\pm$ 1.81	11.20 $\pm$ 2.47 [†]	10.69 $\pm$ 2.02	16.85 $\pm$ 2.27 [†]
Insulin (mIU/l)	16.99 $\pm$ 3.93	18.95 $\pm$ 4.16	28.80 $\pm$ 3.56	35.27 $\pm$ 4.59 [†]

Lrb, leptin receptor. * $P < 0.05$ vs controls and [†] $P < 0.01$ vs controls.

At the end of the study, the glucose tolerance test showed glucose intolerance in the *Lrb*-treated rats on the HFD. There was no difference in glucose tolerance between the scrambled control rats and the *Lrb*-treated rats on the CD (Fig. 4). The leptin concentrations in *Lrb*-shRNA rats were significantly high compared with scrambled shRNA control rats. The concentrations of insulin, fasting glucose, and cholesterol were also significantly increased in *Lrb*-shRNA rats on the HFD. By contrast, the biochemical parameters did not change for the CD rats treated with *Lrb*-shRNA (Table 1).

Effect of *Lrb* knockdown on leptin signaling and *Socs3* mRNA in the ARC

To examine the role of *Lrb* knockdown on leptin signaling, the rats treated with *Lrb*-shRNA or scrambled shRNA were placed on an HFD or CD for 8 weeks. Then the exogenous leptin was injected into rats intraperitoneally and the ARC was examined with western blot analysis. One hour later, Stats3 activation was markedly reduced in *Lrb*-shRNA rats on an HFD or CD in infected regions (Fig. 5A). In addition, the rat treated with *Lrb*-shRNA revealed that leptin-induced *Socs3* mRNA levels were increased in the ARC (Fig. 5B).

Effect of *Lrb* knockdown on gene expression of *Npy* in the ARC

The gene expression of *Npy* was measured by a real-time fluorescence PCR, and the levels of *Npy* mRNA were significantly increased in *Lrb*-shRNA rats on HFD or CD in infected regions (Fig. 6).

Discussion

Leptin is an adipocyte-derived hormone that plays a key role in the regulation of food intake, energy expenditure,

Figure 5

Effect of *Lrb* knockdown on leptin signaling and *Socs3* mRNA in the ARC. Stat3 phosphorylation in the ARC was measured by western blot (A) and *Socs3* mRNA levels (B) were detected via real-time PCR. The white bars represent scrambled control rats, and the black bars represent *Lrb*-shRNA rats. $n=5-6$ per group. The results are shown as mean $\pm$ s.e.m. * $P<0.05$ vs ** $P<0.01$ vs controls. Con, control.

and whole-body energy balance in rodents and humans (Baile *et al.* 2000). Leptin acts through the *Lrb*, of which *Lrb* is the signaling-competent receptor isoform and is expressed most abundantly in paraventricular, arcuate, and ventromedial nuclei of the hypothalamus (Funahashi *et al.* 2003, Bjorbaek & Kahn 2004). Though there are some animal models used for obesity research, such as *ob/ob* mice with leptin deficiency due to mutated leptin gene, and *db/db* mice lacking leptin action due to mutated *Lrb* gene, most human obesities are not associated with deficiency of leptin secretion or *Lrb* bioactivity. Acquired leptin resistance or insensitivity may be a main cause of

human obesity. Our previous studies showed that the obese rats induced by a HFD had hyperleptinemia and reduced expression of *Lrb* in hypothalamus and liver (Liu *et al.* 2007), suggesting that downregulated *Lrb* expression is one of the leptin-resistant mechanisms for maintaining obesity. In order to further study the possible interaction between gene and diet in the development of obesity phenotypes, we used a lentiviral vector-mediated RNAi technique to get long-term gene silencing of *Lrb*. The rats were killed at 8 weeks after viral delivery to ARC, and the EGFP-expressing cells were restricted to the deposition site. The viral delivery induced a significant reduction of *Lrb* mRNA expression in this region. The manipulation selectively reduced the expression of *Lrb* mRNA in the ARC by $\sim 50\%$, which is similar to the previously reported effects of RNAi *in vivo* (Makimura *et al.* 2002) and our study (Liu *et al.* 2011). Thus, incomplete *Lrb* knockdown may have identified a metabolic role for *Lrb* without producing unacceptable side effects. The rats with reduced *Lrb* in ARC showed a significant increase in energy intake and BW in response to the HFD. However, the *Lrb*-shRNA-treated rats did not develop obesity when fed with a low-fat chow. A recent study (Davis *et al.* 2011) showed that reduction of *Lrb* in lateral hypothalamus led to increased food intake and BW gain, an effect that was present only when animals were maintained on a HFD, which is similar to our results. These results raise the possibility that leptin regulates BW homeostasis in a macronutrient-dependent fashion and further stresses the importance of diet in the interplay between gene and diet in the development of obesity

Figure 6

Effect of *Lrb* knockdown on gene expression of *Npy* in the ARC. The gene expression of *Npy* was measured by a real-time fluorescence PCR. The white bars represent scrambled control rats, and the black bars represent *Lrb*-shRNA rats. $n=8-10$ per group. The results are shown as mean $\pm$ s.e.m. * $P<0.01$ vs controls.

phenotypes. Moreover, the obese rats had hyperleptinemia, which was consistent with our previous study (Liu *et al.* 2007). These data proved that knockdown of *Lrb* in the ARC promotes diet-induced obesity and leptin resistance in rats.

Leptin activates cytokine-like signal transduction by stimulation of the JAK–STAT pathway via *Lrb* (Mori *et al.* 2004, Ueki *et al.* 2004). *Socs3* is a member of a family of inhibitory molecules that modulate leptin action through inhibition of pathways downstream of the leptin-activated JAK–STAT pathway (Krebs & Hilton 2001). Our study showed that reduction of *Lrb* in ARC resulted in hyperleptinemia in both the HFD group and the CD group. The *Lrb* knockdown decreased *Stats3* activation and increased expression of *Socs3* and *Npy* in infected regions. These results proved that the *Lrb* knockdown impaired leptin signaling, supported that *Socs3* was involved the etiology of leptin resistance (Myers *et al.* 2008).

Insulin is the second most important adipostatic signal provider to the hypothalamus and acts in the same hypothalamic areas as leptin to suppress feeding (Pliquett *et al.* 2006). There is an interaction between insulin and leptin action in the hypothalamus. In fact, one of the most important functions of insulin in the hypothalamus is to enhance leptin's signal. In the hypothalamus, insulin activates signal transduction through insulin receptor substrate (Schwartz *et al.* 2000, Ueki *et al.* 2004). In addition, insulin induces a potent cross talk with the leptin signaling pathway through the activation of JAK2 (Carvalho *et al.* 2001, Myers *et al.* 2008). In childhood obesity, the serum level of insulin is elevated (Tamura *et al.* 2000). In obesity-prone juvenile rats, *Lrb* mRNA in hypothalamus was reduced by HFD followed by increased leptin and insulin levels (Levin *et al.* 2003). Hyperinsulinemia may be one of the factors for leptin resistance (Seufert 2004). Our previous study showed that HFD induced obesity and hyperinsulinemia (Liu *et al.* 2007). This study showed that the rats treated with *Lrb*-shRNA had high levels of fasting glucose and insulin after exposure to HFD, although the glucose tolerance had no pronounced change, the mild glucose intolerance took into account age and short time of diet-induced obesity. These data proved that diet-induced insulin resistance was further aggravated in rats with *Lrb* reduction. The mechanisms may be that *Lrb* knockdown in the ARC combined with a HFD results in hyperleptinemia, in turn, leads to the activation of intracellular signaling pathways that promote a negative cross talk with the leptin and insulin signaling systems, which

impairs their physiological anorexygenic activities (Carvalho *et al.* 2001). More importantly, the *Lrb* knockdown did not cause the changes in the concentrations of insulin, fasting glucose, and cholesterol of rats on the CD, emphasizing the importance of diet in the interplay between gene and diet in the development of diet-induced obesity and associated metabolic complications. In summary, these results demonstrate that *Lrb* knockdown in the ARC promotes diet-induced obesity and associated insulin resistance in rats, which is helpful to understand the mechanism of leptin resistance in human obesity.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by China Natural Scientific Foundation (nos 30771798 and 81273093).

References

- Augustine RA & Grattan DR 2008 Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion. *Endocrinology* **149** 1049–1055. (doi:10.1210/en.2007-1018)
- Baile CA, Bella-Fera M & Martin RJ 2000 Regulation of metabolism and body fat mass by leptin. *Annual Review of Nutrition* **20** 105–127. (doi:10.1146/annurev.nutr.20.1.105)
- Bjorbaek C & Kahn BB 2004 Leptin signaling in the central nervous system and the periphery. *Recent Progress in Hormone Research* **57** 305–331. (doi:10.1210/rp.59.1.305)
- Carvalho JB, Siloto RM, Ignacchitti I, Brenelli SL, Carvalho CR, Leite A, Velloso LA, Gontijo JA & Saad MJ 2001 Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. *FEBS Letters* **500** 119–124. (doi:10.1016/S0014-5793(01)02591-1)
- Davis JF, Choi DL, Schurdak JD, Fitzgerald MF, Clegg DJ, Lipton JW, Figlewicz DP & Benoit SC 2011 Leptin regulates energy balance and motivation through action at distinct neural circuits. *Biological Psychiatry* **69** 668–674. (doi:10.1016/j.biopsych.2010.08.028)
- Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M & Myers MG Jr 2005 Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. *Molecular Endocrinology* **19** 925–938. (doi:10.1210/me.2004-0353)
- Farooqi S & O'Rahilly S 2006 Genetics of obesity in humans. *Endocrine Reviews* **27** 710–718.
- Fleisch AF, Agarwal N, Roberts MD, Han JC, Theim KR, Vexler A, Troendle J, Yanovski SZ & Yanovski JA 2007 Influence of serum leptin on weight and body fat growth in children at high risk for adult obesity. *Journal of Clinical Endocrinology and Metabolism* **92** 948–954. (doi:10.1210/jc.2006-1390)
- Funahashi H, Yada T, Suzuki R & Shioda S 2003 Distribution, function, and properties of leptin receptors in the brain. *International Review of Cytology* **224** 1–27.
- Galgani J & Ravussin E 2008 Energy metabolism, fuel selection and body weight regulation. *International Journal of Obesity* **32** (Suppl 7) S109–S119. (doi:10.1038/ijo.2008.246)

- Kourtidis A, Eifert C & Conklin DS 2007 RNAi applications in target validation. *Ernst Schering Research Foundation Workshop* **61** 1–21.
- Krebs DL & Hilton DJ 2001 SOCS proteins: negative regulators of cytokine signaling. *Stem Cells* **19** 378–387. (doi:10.1634/stemcells.19-5-378)
- Levin BE, Dunn-Meynell AA, Ricci MR & Cummings DE 2003 Abnormalities of leptin and ghrelin regulation in obesity-prone juvenile rats. *American Journal of Physiology. Endocrinology and Metabolism* **285** E949–E957.
- Liu ZJ, Bian J, Liu J & Endoh A 2007 Obesity reduced the gene expression of leptin receptors in hypothalamus and liver. *Hormone and Metabolic Research* **39** 489–494. (doi:10.1055/s-2007-981680)
- Liu ZJ, Bian J, Wang YC, Zhao YL, Yan D & Wang XX 2009 Construction and identification of lentiviral RNA interference vector of rat leptin receptor gene. *Frontiers of Medicine in China* **3** 57–60. (doi:10.1007/s11684-009-0003-z)
- Liu ZJ, Bian J, Zhao YL, Zhang X, Zou N & Li D 2011 Lentiviral vector-mediated knockdown of SOCS3 in the hypothalamus protects against the development of diet-induced obesity in rats. *Diabetes, Obesity & Metabolism* **13** 885–892. (doi:10.1111/j.1463-1326.2011.01419.x)
- Makimura H, Mizuno TM, Mastaitis JW, Agami R & Mobbs CV 2002 Reducing hypothalamic AGRP by RNA interference increases metabolic rat and decreases body weight with influencing food intake. *BMC Neuroscience* **3** 18–23. (doi:10.1186/1471-2202-3-18)
- Makinen PI, Koponen JK, Karkkainen AM, Malm TM, Pulkkinen KH, Koistinaho J, Tarunen MP & Yla-Herttuala S 2006 Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. *Journal of Gene Medicine* **8** 433–441. (doi:10.1002/jgm.860)
- Martin RL, Perex E, He Y, Dawson R Jr & Millard WJ 2000 Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein down-regulation. *Metabolism* **9** 1479–1484. (doi:10.1053/meta.2000.17695)
- Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H & Yoshimura A 2004 Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. *Nature Medicine* **10** 739–743. (doi:10.1038/nm1071)
- Myers MG, Cowley MA & Munzberg H 2008 Mechanisms of leptin action and leptin resistance. *Annual Review of Physiology* **70** 537–556. (doi:10.1146/annurev.physiol.70.113006.100707)
- Nakanishi T, Li R, Liu Z, Nakagawa MY & Ohzeki T 2001 Sexual dimorphism in relationship of serum leptin and relative weight for the standard in normal-weight, but not in overweight children as well as adolescents. *European Journal of Clinical Nutrition* **55** 989–993. (doi:10.1038/sj.ejcn.1601257)
- Palkovits M 1973 Isolated removal of hypothalamic or other brain nuclei of the rat. *Brain Research* **59** 449–450. (doi:10.1016/0006-8993(73)90290-4)
- Picardi PK, Calegari VC, Prada Pde O, Moraes JC, Araujo E, Marcondes MC, Veno M, Carvalheira JB, Velloso LA & Saad MJ 2008 Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats. *Endocrinology* **149** 3870–3880. (doi:10.1210/en.2007-1506)
- Pliquett RU, Führer D, Falk S, Zysset S, von Cramon DY & Stumvoll M 2006 The effects of insulin on the central nervous system-focus on appetite regulation. *Hormone and Metabolic Research* **38** 442–446. (doi:10.1055/s-2006-947840)
- Schwartz MW, Woods SC, Porte DJ, Seeley RJ & Baskin DG 2000 Central nervous system control of food intake. *Nature* **404** 661–671.
- Seufert J 2004 Leptin effects on pancreatic β -cell gene expression and function. *Diabetes* **53** S152–S158. (doi:10.2337/diabetes.53.2007.S152)
- Tamura A, Mori T, Hara Y & Komiyama A 2000 Preperitoneal fat thickness in childhood obesity: association with serum insulin concentration. *Pediatrics International* **42** 155–159. (doi:10.1046/j.1442-200x.2000.01197.x)
- Ueki K, Kondo T & Kahn CR 2004 Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. *Molecular and Cellular Biology* **24** 5434–5446. (doi:10.1128/MCB.24.12.5434-5446.2004)
- Widdowson PS, Upton R, Buckingham R, Arch J & Williams G 1997 Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. *Diabetes* **46** 1782–1785. (doi:10.2337/diabetes.46.11.1782)

Received in final form 26 March 2013

Accepted 2 April 2013

Accepted Preprint published online 2 April 2013